Clinical trial · Observational
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual
Summary
Brief summary (as posted)
Among patients with advanced (metastatic) cancers, detailed characterizations of the tumor utilizing genomic and proteonomic techniques may help guide treatment. It, however, remains unclear if these new diagnostic technologies truly influence clinical and economic outcomes. This study will evaluate if patients treated according to the results of the NantHealth GPS Cancer test achieve optimal outcomes compared to patients whose treatment are discordant with GPS Cancer recommendations.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Colon Cancer | Malignant Colon Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NantHealth GPS Cancer Test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Concordant with GPS Cancer Test
- description
- Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
- interventionNames
- Diagnostic Test: NantHealth GPS Cancer Test
- label
- Discordant with GPS Cancer Test
- description
- Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
- interventionNames
- Diagnostic Test: NantHealth GPS Cancer Test
- label
- CNA controls without testing
- description
- Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic cancer patients ineligible for curative surgery at time of entry will be eligible for enrollment. * Metastatic breast cancer at any time in their treatment history will be eligible for enrollment. * Advanced stage (non-resectable/metastatic/incurable) lung cancer patients will be eligible for enrollment. * Metastatic colon cancer patients not amenable to curative therapy will be eligible for enrollment. * Metastatic non-resectable malignant melanoma patients will be eligible for enrollment. NantHealth GPS Cancer in Advanced Cancers * Metastatic hormone refractory prostate cancer patients will be eligible for enrollment. Patients must have tumor tissue available prior to the initiation of the current line of treatment available for GPS Cancer testing. * Metastatic bladder cancer * Non-resectable metastatic Renal carcinoma * Non-resectable metastatic Head and Neck cancer * Metastatic Ovarian cancer * Metastatic Cervical cancer * Metastatic Sarcoma * Patients must sign informed consent for this study. * Patients must have private medical insurance coverage through Horizon Blue Cross Blue Shield. This is limited to insured commercial members, including HMO, and excluding, for the avoidance of doubt, members of self-insured customers or Medicare or Medicaid programs. Exclusion Criteria: * Pregnancy.
References
Publications (0)
Data not yet available